ReviewTuberculosis (Edinburgh, Scotland)2015
The microbiome at the pulmonary alveolar niche and its role in Mycobacterium tuberculosis infection.
Review in Tuberculosis (Edinburgh, Scotland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04079400 (Microbiome in Patients With Pulmonary Tuberculosis, Non-tuberculous Mycobacterial Pulmonary Diseases), which is not on this map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Microbiome in Patients With Pulmonary Tuberculosis, Non-tuberculous Mycobacterial Pulmonary Diseases (NTM-PD), Lung Cancer and Hemoptysis
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Application of Metagenomic Next-Generation Sequencing inFrontiers in medicine · 2022Pooled it
- Methods for Detecting Mycobacterial Mixed Strain Infections-A Systematic Review.Frontiers in genetics · 2020Pooled it
- Dysbiosis associated with enhanced microbial mobility across the respiratory tract in pulmonary tuberculosis patients.BMC microbiology · 2025Article
- The gut and lung microbiome across the TB disease spectrum.Frontiers in microbiology · 2025Review
- Dynamic changes of respiratory microbiota associated with treatment outcome in drug-sensitive and drug-resistant pulmonary tuberculosis.Annals of clinical microbiology and antimicrobials · 2024Article
- The Interplay betweenClinics and practice · 2024Review
- Unravelling the gut-lung axis: insights into microbiome interactions and Traditional Indian Medicine's perspective on optimal health.FEMS microbiology ecology · 2023Review
- Unlocking the Potential of the Human Microbiome for Identifying Disease Diagnostic Biomarkers.Diagnostics (Basel, Switzerland) · 2022Review
- The Microbiome as Part of the Contemporary View of Tuberculosis Disease.Pathogens (Basel, Switzerland) · 2022Review
- The Role of Gut and Lung Microbiota in Susceptibility to Tuberculosis.International journal of environmental research and public health · 2021Review
- Microbiota and Tuberculosis: A Potential Role of Probiotics, and Postbiotics.Frontiers in nutrition · 2021Review
- Protein and Microbial Biomarkers in Sputum Discern Acute and Latent Tuberculosis in Investigation of Pastoral Ethiopian Cohort.Frontiers in cellular and infection microbiology · 2021Article
- Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.Mediators of inflammation · 2019Review
- Gut microbes as future therapeutics in treating inflammatory and infectious diseases: Lessons from recent findings.The Journal of nutritional biochemistry · 2018Review
- Immunological roulette: Luck or something more? Considering the connections between host and environment in TB.Cellular & molecular immunology · 2018Review
- The Host Microbiota Contributes to Early Protection Against Lung Colonization byFrontiers in immunology · 2018Article
- Airway Macrophage and Dendritic Cell Subsets in the Resting Human Lung.Critical reviews in immunology · 2018Review
- The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomes.Tuberculosis (Edinburgh, Scotland) · 2017Observational
- Transcriptional Classification and Functional Characterization of Human Airway Macrophage and Dendritic Cell Subsets.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Microbiome Changes during Tuberculosis and Antituberculous Therapy.Clinical microbiology reviews · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Advances in next generation sequencing (NGS) technology have provided the tools to comprehensively and accurately characterize the microbial community in the respiratory tract in health and disease. The presence of commensal and pathogenic bacteria has been found to have important effects on the lung immune system. Until relatively recently, the lung has received less attention compared to other body sites in terms of microbiome characterization, and its study carries special technological difficulties related to obtaining reliable samples as compared to other body niches. Additionally, the complexity of the alveolar immune system, and its interactions with the lung microbiome, are only just beginning to be understood. Amidst this complexity sits Mycobacterium tuberculosis (Mtb), one of humanity's oldest nemeses and a significant public health concern, with millions of individuals infected with Mtb worldwide. The intricate interactions between Mtb, the lung microbiome, and the alveolar immune system are beginning to be understood, and it is increasingly apparent that improved treatment of Mtb will only come through deep understanding of the interplay between these three forces. In this review, we summarize our current understanding of the lung microbiome, alveolar immunity, and the interaction of each with Mtb.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.